PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21411542-2	2011	Despite significant progress in understanding the structural features of the HIV-1 envelope glycoprotein (Env) and the discovery of multiple broadly neutralizing monoclonal antibodies with defined antigenic structures, the design of optimal Env immunogens to elicit broad NAbs remains a major challenge.	nabs	272-276	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	241-244	
25589637-1	2015	UNLABELLED: Recombinant trimeric mimics of the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) spike should expose as many epitopes as possible for broadly neutralizing antibodies (bNAbs) but few, if any, for nonneutralizing antibodies (non-NAbs).	nabs	206-210	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	91-112	
25589637-1	2015	UNLABELLED: Recombinant trimeric mimics of the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) spike should expose as many epitopes as possible for broadly neutralizing antibodies (bNAbs) but few, if any, for nonneutralizing antibodies (non-NAbs).	nabs	206-210	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	114-117	
23394346-3	2013	Standard methods for evaluating HIV-1 vaccine candidates do not enable epitope mapping on the HIV Env spike, the target for NAbs.	nabs	124-128	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	98-101	
22693447-3	2012	In each of the subjects, Nabs targeted different regions of the HIV-1 envelope (Env) in a strain-specific, conformationally sensitive manner.	nabs	25-29	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	80-83	
22693447-9	2012	Although delayed in comparison with autologous CD8 T-cell responses, our findings show that Nabs appear earlier in HIV-1 infection than previously recognized, target diverse sites on HIV-1 Env, and impede virus replication at surprisingly low titers.	nabs	92-96	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	189-192	
21128886-3	2010	The primary target for nAbs on HIV-1 is the envelope glycoprotein spike (Env).	nabs	23-27	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	73-76	
21128886-7	2010	Increased understanding of antibody epitope exposure on Env should provide new impulses for efforts to elicit nAbs that can protect against HIV-1 infection.	nabs	110-114	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	56-59	
31049300-4	2019	Efficient cleavage of the HIV-1 Env precursor gp160 polypeptide into its constituent subunits determines its ability to selectively bind to bNAbs and poorly to non-NAbs (non-neutralizing antibodies), properties desirable in Env-based immunogens.	nabs	141-145	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	32-35	
31049300-4	2019	Efficient cleavage of the HIV-1 Env precursor gp160 polypeptide into its constituent subunits determines its ability to selectively bind to bNAbs and poorly to non-NAbs (non-neutralizing antibodies), properties desirable in Env-based immunogens.	nabs	141-145	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	46-51	
21799765-3	2011	We vaccinated rhesus macaques with recombinant simian immunodeficiency virus (SIV) Gag-Pol particles, HIV-1 Tat and trimeric clade C (HIV-C) gp160, which induced cross-neutralizing antibodies (nAbs) and robust cellular immune responses.	nabs	193-197	Envelope surface glycoprotein gp160, precursor	Human immunodeficiency virus 1	141-146